Nibbling at CRF receptor control of feeding and gastrocolonic motility

被引:123
作者
Zorrilla, EP
Taché, Y
Koob, GF
机构
[1] Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA
[2] Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90073 USA
[3] VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA
关键词
D O I
10.1016/S0165-6147(03)00177-9
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Inadequate pharmacological tools, until recently, hindered the understanding of the roles of corticotropin-releasing factor (CRF) receptor subtypes in appetite regulation and gastrocolonic motor function. Now, novel ligands that are selective for CRF1 or CRF2 receptors are helping to uncover the specific functions of CRF receptor subtypes. Central or peripheral CRF2 receptor activation suppresses feeding independently of CRF1 receptors. In the rat, central administration of CRF2 receptor agonists promotes satiation without eliciting the malaise, behavioral arousal or anxiogenesis associated with CRF, receptor agonists. Conversely, central administration of CRF1 receptor agonists elicits short-onset anorexia independently of CRF2 receptor activation. With respect to gastrointestinal motor function, stress inhibits gastric motility through CRF2 receptor-dependent central autonomic and peripheral myenteric systems. By contrast, stress stimulates colonic motility via CRF, receptor-dependent sacral parasympathetic and colonic myenteric mechanisms. These findings have important physiological implications and suggest targeted approaches for the pharmacotherapy of obesity and stress-related functional gastrointestinal and eating disorders.
引用
收藏
页码:421 / 427
页数:7
相关论文
共 60 条
[1]
Characterization of three corticotropin-releasing factor receptors in catfish: A novel third receptor is predominantly expressed in pituitary and urophysis [J].
Arai, M ;
Assil, IQ ;
Abou-Samra, AB .
ENDOCRINOLOGY, 2001, 142 (01) :446-454
[2]
Bittencourt JC, 1999, J COMP NEUROL, V415, P285
[3]
Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity [J].
Brauns, O ;
Brauns, S ;
Jenke, M ;
Zimmermann, B ;
Dautzenberg, FM .
PEPTIDES, 2002, 23 (10) :1817-1827
[4]
Intravenous urocortin II decreases blood pressure through CRF2 receptor in rats [J].
Chen, CY ;
Doong, ML ;
Rivier, JE ;
Taché, Y .
REGULATORY PEPTIDES, 2003, 113 (1-3) :125-130
[5]
Intracisternal urocortin inhibits vagally stimulated gastric motility in rats:: role of CRF2 [J].
Chen, CY ;
Million, M ;
Adelson, DW ;
Martínez, V ;
Rivier, J ;
Taché, Y .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (02) :237-247
[6]
Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2 [J].
Coste, SC ;
Kesterson, RA ;
Heldwein, KA ;
Stevens, SL ;
Heard, AD ;
Hollis, JH ;
Murray, SE ;
Hill, JK ;
Pantely, GA ;
Hohimer, AR ;
Hatton, DC ;
Phillips, TJ ;
Finn, DA ;
Low, MJ ;
Rittenberg, MB ;
Stenzel, P ;
Stenzel-Poore, MP .
NATURE GENETICS, 2000, 24 (04) :403-409
[7]
The CRF peptide family and their receptors: yet more partners discovered [J].
Dautzenberg, FM ;
Hauger, RL .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (02) :71-77
[8]
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-α]-pyrimidine:: A corticotropin-releasing factor (hCRF1) antagonist [J].
Gilligan, PJ ;
Baldauf, C ;
Cocuzza, A ;
Chidester, D ;
Zaczek, R ;
Fitzgerald, LW ;
McElroy, J ;
Smith, MA ;
Shen, HSL ;
Saye, JA ;
Christ, D ;
Trainor, G ;
Robertson, DW ;
Hartig, P .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (01) :181-189
[9]
Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents [J].
Gilligan, PJ ;
Robertson, DW ;
Zaczek, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1641-1660
[10]
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A):: A potent and selective corticotrophin-releasing factor1 receptor antagonist.: I.: Biochemical and pharmacological characterization [J].
Gully, D ;
Geslin, M ;
Serva, L ;
Fontaine, E ;
Roger, P ;
Lair, C ;
Darre, V ;
Marcy, C ;
Rouby, PE ;
Simiand, J ;
Guitard, J ;
Gout, G ;
Steinberg, R ;
Rodier, D ;
Griebel, G ;
Soubrie, P ;
Pascal, M ;
Pruss, R ;
Scatton, B ;
Maffrand, JP ;
Le Fur, G .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :322-332